National take-back days have allowed participating agencies to take more than 4.1 million pounds of unwanted or expired prescription medications out of circulation since DEA

FDA Seeks Nominations for Bulk Drug Substance List

The Drug Quality and Security Act signed into law on Nov. 27 created a new category of "outsourcing facilities" that may compound drugs, either by or under the direct supervision of a licensed pharmacist.

The U.S. Food and Drug Administration is accepting nominations for a bulk drug substance list that is required by the newly enacted Drug Quality and Security Act. After the fungal meningitis outbreak of 2012 linked to the New England Compounding Center, this law was written to clarify FDA's authority to regulate compounded drugs and creates a new, voluntary program for FDA to regulate entities engaged in batch compounding so they can register with the agency.

A new section established by the act says outsourcing facilities may not compound using a bulk drug substance unless that substance is on the list established by the HHS secretary and identifying bulk drug substances for which there is a clinical need, or the drug compounded from such bulk drug substance appears on the drug shortage list in effect under section 506E of the FD&C Act at the time of compounding, distribution, and dispensing, along with two other possible ways substances may be used.

FDA's request for specific substance nominations say this information should be supplied:

  • Ingredient name
  • Chemical name
  • Common name(s)
  • Chemical grade or description of the strength, quality, and purity of the ingredient
  • Information about how the ingredient is supplied (e.g., powder, liquid
  • Information about recognition of the substance in foreign pharmacopeias and the status of its registration(s) in other countries, including whether information has been submitted to USP for consideration of monograph development
  • A bibliography of available safety and efficacy data,2 including any relevant peer-reviewed medical literature
  • An explanation of why there is a clinical need to compound from the bulk drug substance

For a compounded product, the necessary information is:

  • Information about the dosage form(s) into which the drug substance will be compounded (including formulations)
  • Information about the strength(s) of the compounded product(s)
  • Information about the anticipated route(s) of administration of the compounded product(s)
  • Information about the past and proposed use(s) of the compounded product(s), including the rationale for its use or why the compounded product(s), as opposed to an FDA-approved product, is necessary
  • Available stability data for the compounded product(s)

Submissions received must identify FDA and also Docket No. FDA-2013-N-1524. Check that number at www.regulations.gov for submitted substances/products.

Download Center

HTML - No Current Item Deck
  • Safety Management Software - Free Demo

    IndustrySafe Safety Software’s comprehensive suite of modules help organizations to record and manage incidents, inspections, hazards, behavior based safety observations, and much more. Improve safety with an easy to use tool for tracking, notifying and reporting on key safety data.

  • Create Flexible Safety Dashboards

    IndustrySafe’s Dashboard Module allows organizations allows you to easily create and view safety KPIs to help you make informed business decisions. Our best of breed default indicators can also save you valuable time and effort in monitoring safety metrics.

  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • The 4 Stages of an Incident Investigation

    So, your workplace has just experienced an incident resulting in the injury or illness of a worker. Now what? OSHA recommends that you conduct investigations of workplace incidents using a four-step system.

  • Why Is Near Miss Reporting Important?

    A near miss is an accident that's waiting to happen. Learn how to investigate these close calls and prevent more serious incidents from occurring in the future.

  • Industry Safe
comments powered by Disqus

Free Whitepaper

Stand Your Ground: A Guide to Slip Resistance in Industrial Safety Footwear

This white paper helps to clarify this complexity, so you can better navigate the standards and better ensure the safety of your employees.

Download Now →

OH&S Digital Edition

  • OHS Magazine Digital Edition - November December 2019

    November/December 2019

    Featuring:

    • GAS DETECTION
      Redefining Compliance for the Gas Detection Buyer
    • FALL PROTECTION
      Don't Trip Over the Basics
    • VISION PROTECTION
      What to Look for in Head-to-Toe PPE Solutions
    • PROTECTIVE APPAREL
      Effective PPE for Flammable Dust
    View This Issue